Common Psychiatric Medications May Increase Risk of ALS

Common Psychiatric Medications May Increase Risk of ALS

New research shows that people who take certain psychiatric medications may be more likely to develop amyotrophic lateral sclerosis (ALS), which is the most common form of motor neurone disease (MND).

NextGenALS planning golf jamboree to fund ALS research

By Brian Roebke Editor When Art Weber passed away from ALS in 1999, he left a lifetime of love and memories with his family but he also left behind a terrible disease that afflicted his children.     Full text available to subscribers only. If you are a current subscriber, please use the login below to continue reading this article. To become a subscriber, please click here.

Study reveals possible link between some psychiatric drugs and ALS

ALS Risk Factors Linked to Certain Antidepressants, Anti-Anxiety Drugs: Study

Patients taking at least two psychiatric drugs had a greater risk of developing ALS than other individuals, even if the medications were prescribed more than five years earlier. New research suggests that certain kinds of psychiatric medications can increase an individual’s chance of developing amyotrophic lateral sclerosis (ALS) by as much as sixfold. The fi…

State orders mandatory reporting of ALS cases

The Michigan Department of Health and Human Services has adopted a new rule regarding the reporting of cases of ALS. The fatal condition also known as Lou Gehrig’s disease has no cure and causes people to eventually lose their ability to move and speak. The new rule requires mandatory reporting for cases of ALS in Michigan. The rule went into effect in May, making Michigan the fifth state in the U.S. to implement mandatory ALS case reporting, wh…

AMX0114 receives FDA fast track status for the treatment of ALS

The U.S. Food and Drug Administration (FDA) has granted fast track designation to AMX0114, an experimental therapy being developed by Amylyx Pharmaceuticals, for the treatment of amyotrophic lateral sclerosis (ALS). Fast track status is designed to facilitate the development and review of treatments that have the potential to address serious or life-threatening conditions and unmet medical needs. The designation will enable Amylyx to have more f…